Agios Pharmaceuticals, Inc.
Cambridge
Massachusetts
United States
363 articles about Agios Pharmaceuticals, Inc.
-
Agios To Present Clinical And Preclinical Data At The 20th Congress Of The European Hematology Association
5/21/2015
-
Agios Announces FDA Fast Track Designation Granted To AG-120 For Treatment Of Patients With Acute Myelogenous Leukemia With An IDH1 Mutation
5/18/2015
-
Celgene Dealmaking Continues With Two Pacts Worth $110 Million With Agios, Northern Biologics
4/30/2015
-
Agios To Webcast Conference Call Of First Quarter 2015 Financial Results On May 7, 2015
4/29/2015
-
Agios Pharmaceuticals Announces Orphan Drug Designation Of AG-348 For Treatment Of Pyruvate Kinase Deficiency
3/25/2015
-
Agios Pharmaceuticals To Present At Cowen and Company 35th Annual Health Care Conference On Monday, March 2
2/20/2015
-
Agios Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results
2/17/2015
-
Agios Pharmaceuticals To Webcast Conference Call Of Fourth Quarter And Full Year 2014 Financial Results On February 17, 2015
2/10/2015
-
Agios Pharmaceuticals To Present At The 2015 Leerink Global Healthcare Conference On Wednesday, February 11
2/3/2015
-
Agios Pharmaceuticals Announces That Celgene Has Agreed To Exercise Its Option To License AG-120 Under Global Strategic Collaboration
1/13/2015
-
Agios Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference On Monday, January 12
1/6/2015
-
Agios Pharmaceuticals Announces Closing Of Public Offering And Full Exercise Of Over-Allotment Option
12/17/2014
-
Agios Pharmaceuticals Announces Pricing Of $220 Million Public Offering Of Common Stock
12/11/2014
-
Agios Pharmaceuticals Appoints Kaye Foster-Cheek To Its Board Of Directors
12/10/2014
-
Agios Pharmaceuticals Announces Proposed Offering Of Common Stock
12/10/2014
-
Agios Pharmaceuticals Reports Positive Phase 1 Data In Healthy Volunteers For AG-348, A First-In-Class Investigational Medicine That Targets The Underlying Cause Of Pyruvate Kinase (PK) Deficiency
12/9/2014
-
Agios Pharmaceuticals Announces New Data From Ongoing Phase 1 Trial Of AG-221 Showing Robust Clinical Activity In Patients With Advanced Hematologic Malignancies
12/8/2014
-
Agios Pharmaceuticals Announces Celgene Decision To Extend Discovery Phase Of Global Strategic Collaboration To April 2016
12/8/2014
-
Agios Pharmaceuticals Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML)
11/18/2014
-
Citi: Agios Pharmaceuticals’s Experimental Cancer Drug Could Provide Major Upside
11/10/2014